Assessing the clinical and bacteriological outcomes of vaccination with recombinant Asp14 and OmpA against A. phagocytophilum in sheep

Publication date: Available online 11 September 2019Source: Veterinary Immunology and ImmunopathologyAuthor(s): Sveinung Eskeland, Snorre Stuen, Francy L. Crosby, Kari Lybeck, Anthony F. Barbet, Per-Eric Lindgren, Stig Tollefsen, Peter Wilhelmsson, Tore S. Tollersrud, Shokouh Makvandi-Nejad, Erik G. GranquistAbstractAnaplasma phagocytophilum is a tick borne bacterium, causing disease in sheep and other mammals, including humans. The bacterium has great economic and animal welfare implications for sheep husbandry in Northern Europe. With the prospect of a warmer and more humid climate, the vector availability will likely increase, resulting in a higher prevalence of A. phagocytophilum. The current preventive measures, as pyrethroids acting on ticks or long acting antibiotics controlling bacterial infection, are suboptimal for prevention of the disease in sheep. Recently, the increased awareness on antibiotic- and pyrethorid resistance, is driving the search for a new prophylactic approach in sheep against A.phagocytophilum.Previous studies have used an attenuated vaccine, which gave insufficient protection from challenge with live bacteria. Other studies have focused on bacterial membrane surface proteins like Asp14 and OmpA. An animal study using homologous proteins to Asp14 and OmpA of A. marginale, showed no protective effect in heifers. In the current study, recombinant proteins of Asp14 (rAsp14) and OmpA (rOmpA) of A. phagocytophilum were produced and prepared as a vaccin...
Source: Veterinary Immunology and Immunopathology - Category: Veterinary Research Source Type: research